These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15868022)

  • 21. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
    Ridley DB; Sánchez AC
    Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
    Arno PS; Bonuck K; Davis M
    Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial lessons from public-private partnerships in drug and vaccine development.
    Wheeler C; Berkley S
    Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What are today's orphaned vaccines?
    Wilde H
    Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulating research and development of pharmaceutical products for neglected diseases.
    Stirner B
    Eur J Health Law; 2008 Dec; 15(4):391-409. PubMed ID: 19180979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making health markets work better for poor people: the case of informal providers.
    Bloom G; Standing H; Lucas H; Bhuiya A; Oladepo O; Peters DH
    Health Policy Plan; 2011 Jul; 26 Suppl 1():i45-52. PubMed ID: 21729917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The distribution of sales revenues from pharmaceutical innovation.
    Grabowski HG; Vernon J
    Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BioShield defence programme set to fund anthrax vaccine.
    Check E
    Nature; 2004 May; 429(6987):4. PubMed ID: 15129240
    [No Abstract]   [Full Text] [Related]  

  • 37. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nursing home performance under case-mix reimbursement: responding to heavy-care incentives and market changes.
    Davis MA; Freeman JW; Kirby EC
    Health Serv Res; 1998 Oct; 33(4 Pt 1):815-34. PubMed ID: 9776938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orphan products: drugs and devices for rare diseases.
    Pillar B
    Nurs Econ; 1993; 11(2):99-102. PubMed ID: 8502310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.